William Blair
http://www.williamblair.comWilliam Blair & Company, L.L.C. is a Chicago-based investment firm offering investment banking, asset management, equity research, institutional and private brokerage, and private capital to individual, institutional, and issuing clients. Since 1935, it has been committed to helping clients achieve their financial objectives.
-
Autolus Announces Pricing of Public Offering
-
Autolus Announces Pricing of Public Offering
-
Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
-
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
-
Reaction Biology Announces Closing of Growth Investment from Cobepa and Chief Executive Officer Transition
-
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
-
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021
-
Autolus Announces Closing of Public Offering
-
Autolus Announces Closing of Public Offering
-
Autolus Therapeutics (AUTL) Prices 7.25M ADS Offering at $11/ADS
-
Autolus Announces Pricing of Public Offering
-
Autolus Announces Pricing of Public Offering
-
Autolus Therapeutics (AUTL) Announces 7.25M Proposed Public Offering of ADSs
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Autolus Therapeutics (AUTL) Prices 4.2M ADS Offering at $24/ADS
-
Autolus Announces Pricing of Public Offering
-
Autolus Announces Pricing of Public Offering
-
Autolus Therapeutics (AUTL) Plans Offering of 4M ADSs
-
Autolus Announces Proposed Public Offering in the United States
-
Autolus Announces Proposed Public Offering in the United States
-
William Blair Starts AUTL (AUTL) at Outperform
-
Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Autolus Therapeutics (AUTL) IPO Opens 65% Higher

